Los Angeles Capital Management
BOLD

Los Angeles Capital Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Los Angeles Capital Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6,080
Closed -$232K – 1538
2018
Q2 		$232K Buy
+6,080
New +$225K ﹤0.01% 1349

Other funds holding BOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Los Angeles Capital Management's BOLD Position: Q3 2018 in Review

Los Angeles Capital Management sold out of Audentes Therapeutics, Inc (BOLD) in Q3 2018, closing a stake of 6,080 shares — an estimated $232K sold.

Los Angeles Capital Management first reported a position in BOLD in Q2 2018 and held it in 1 quarter. The position peaked at $232K in Q2 2018. 114 funds tracked by Wall St. Rank hold BOLD as of Q3 2018.

  • Los Angeles Capital Management reported no remaining Audentes Therapeutics, Inc position as of Q3 2018 after selling out during the quarter.
  • Los Angeles Capital Management sold 6,080 Audentes Therapeutics, Inc shares in Q3 2018, an estimated $232K.
  • Los Angeles Capital Management first reported a position in Audentes Therapeutics, Inc in Q2 2018 and held it in 1 quarter.
  • Los Angeles Capital Management's Audentes Therapeutics, Inc position peaked at $232K in Q2 2018.
  • 114 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q3 2018.

Based on Los Angeles Capital Management's 13F filing for Q3 2018, filed 5 Nov 2018.